1. Home
  2. CABR vs IMNN Comparison

CABR vs IMNN Comparison

Compare CABR & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CABR

Caring Brands Inc.

N/A

Current Price

$1.12

Market Cap

9.5M

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$2.25

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABR
IMNN
Founded
2020
1982
Country
United States
United States
Employees
3
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5M
10.8M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CABR
IMNN
Price
$1.12
$2.25
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
86.0K
36.0K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.48
52 Week High
$1.65
$9.32

Technical Indicators

Market Signals
Indicator
CABR
IMNN
Relative Strength Index (RSI) 59.87 19.78
Support Level $0.79 N/A
Resistance Level $1.32 $3.24
Average True Range (ATR) 0.10 0.17
MACD 0.02 -0.04
Stochastic Oscillator 94.09 7.79

Price Performance

Historical Comparison
CABR
IMNN

About CABR Caring Brands Inc.

Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: